Navigation Links
BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
Date:9/23/2010

NOVATO, Calif., Sept. 23 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today the appointment of William D. Young and Kenneth M. Bate to its Board of Directors.

"We are extremely pleased to welcome William Young and Kenneth Bate to our Board of Directors.  With experience, vision and proven strength in leadership and execution, they are both exceptionally qualified to take on this important role in the company," said Pierre Lapalme, Chairman of the Board of Directors of BioMarin. "With four products on the market and six product candidates in the clinic by early next year, BioMarin is the busiest it has ever been, and I am confident that Mr. Young and Mr. Bate will serve as valuable leaders and contributors to the growth of the company during this exciting time."

Mr. William D. Young is a Venture Partner at Clarus Ventures of San Francisco and Boston. He was appointed Chairman of the Board of Biogen Idec in January 2010 and began serving as a Director of IDEC Pharmaceuticals in 1997. From 1999 to October 2009, Mr. Young was Chairman and Chief Executive Officer for Monogram Biosciences, Inc., a pioneer in the field of personalized medicine. From 1997 to 1999, Mr. Young served as Chief Operating Officer of Genentech, Inc. Mr. Young joined Genentech in 1980 as Director of Manufacturing and Process Sciences and became Vice President in 1983. He was promoted to various positions and, in 1997, became Chief Operating Officer, taking on responsibility for all development, operations and sales and marketing activities. Prior to joining Genentech, Mr. Young was with Eli Lilly & Co. for 14 years. Mr. Young holds a B.S. in Chemical Engineering from Purdue University and a M.B.A. from Indiana University and an Honorary Doctorate in Engineering from Purdue University. He is also a Director of Theravance, Inc. Mr. Young was elected to the National Academy of Engineering in 1993 for his contributions to biotechnology

Mr. Kenneth Bate is President and Chief Executive Officer of Archemix, a privately-held biotechnology company engaged in discovering and developing aptamer therapeutics to treat chronic and acute diseases. From 2006 to 2009 Mr. Bate was with NitroMed, Inc., most recently as President and Chief Executive Officer of the company. From 2002 to 2005 he was with Millennium Pharmaceuticals where he was chief financial officer and headed the firm's commercial organization. Prior to Millennium, Mr. Bate co-founded JSB Partners, a banking and advisory services firm for biopharmaceutical and life sciences companies. From 1990 to 1996 he was with Biogen, Inc first as chief financial officer then as head of the commercial organization responsible for launching its multiple sclerosis business. Mr. Bate received his B.A. in Chemistry from Williams College and his M.B.A. from the Wharton School of the University of Pennsylvania. He is currently on the board of AVEO Pharmaceuticals and is Lead Director of Cubist Pharmaceuticals.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Eugenia ShenBioMarin Pharmaceutical Inc.(415) 506-6570
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin to Present at the UBS Global Life Sciences Conference
2. BioMarin to Present at the Stifel Nicolaus Healthcare Conference
3. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
4. BioMarin Acquires ZyStor Therapeutics, Inc.
5. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
6. BioMarin to Acquire LEAD Therapeutics
7. BioMarin to Present at the Credit Suisse Healthcare Conference
8. BioMarin Announces Third Quarter 2009 Financial Results
9. BioMarin to Present at the Oppenheimer Healthcare Conference
10. BioMarin Acquires Huxley Pharmaceuticals, Inc.
11. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... New York , March 29, 2017 /PRNewswire/ ... recently published a report, which provides an exhaustive ... to the study, nearly 242 companies are functional ... fragmented and competitive. With the leading companies, such ... Purdue Pharma LP, focusing aggressively on various marketing ...
(Date:3/29/2017)... Research and Markets has announced the addition of the ... ... drugs market to grow at a CAGR of 2.87% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:3/29/2017)... March 29, 2017 Varian Medical Systems (NYSE: ... for the second quarter of fiscal year 2017 following the ... news release will be followed by a teleconference available to ... and a link to the conference call webcast will be ... access the teleconference call and replay: ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... ... VisualSP has helped over 1.5 million SharePoint users learn the content management system ... Help System for SharePoint was at the farm level. Enterprises using SharePoint Online in ... The company recently released a modified version of the Help System, VisualSP for Site ...
(Date:3/28/2017)... ... March 28, 2017 , ... Tuesday, March 28, 2017, is the annual American ... Diabetes Risk Test to find out if they are at risk for developing Type ... up the evening sky by programming the LAX pylons the color red. Downtown’s U.S. ...
(Date:3/28/2017)... ... March 28, 2017 , ... India’s ... technology to directly address the resolution to globally reduce the harmful use of ... compound of FDA and TTB approved ingredients that when infused into alcohol, renders ...
(Date:3/28/2017)... ... 2017 , ... Resoundant, Inc., the developer of Magnetic ... annual customer education symposium, a world-class learning conference that offers educational content designed ... 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , Innovations for ...
(Date:3/28/2017)... ... March 29, 2017 , ... The Thyroid ... Isabella Wentz, Pharm.D., FASCP. The program was recently launched on March 1, and ... regarding thyroid function. , Dr. Izabella Wentz is a licensed pharmacist and ...
Breaking Medicine News(10 mins):